PURPOSE: There is no available tumor marker that can detect primary melanoma. Proteomics analysis has been proposed as a novel tool that would lead to the discovery of potential new tumor markers. METHODS: We developed a serum proteomic fingerprinting approach coupled with a classification method to determine whether proteomic profiling could discriminate between melanoma and healthy volunteers. A total of 108 serum samples from 30 early-stage [American Joint Committee on Cancer (AJCC) stage I or II] and 30 advanced-stage (AJCC stage III or IV) melanoma patients and 48 healthy volunteers were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) utilizing protein chip technology and artificial neural networks. RESULTS: In a first step, a multiprotein classifier was built using a training set of 30 pathologically confirmed melanoma and 24 healthy volunteer serum samples, resulting in good classification accuracy for correct diagnosis and stage classification assignment. Subsequently, our multiprotein classifier was tested in an independent validation set of 30 melanoma and 24 non-cancer serum samples patients, maintained in a good diagnostic accuracy of 98.1% (sensitivity 96.7%, specificity 100%), and 100% stage I/II classification assignment. CONCLUSIONS: Although results remain to be confirmed in larger collective patient cohorts, we could demonstrate the usefulness of proteomic profiling as a sensitive and specific assay to detect melanoma, including non-metastatic melanoma, from the serum.
PURPOSE: There is no available tumor marker that can detect primary melanoma. Proteomics analysis has been proposed as a novel tool that would lead to the discovery of potential new tumor markers. METHODS: We developed a serum proteomic fingerprinting approach coupled with a classification method to determine whether proteomic profiling could discriminate between melanoma and healthy volunteers. A total of 108 serum samples from 30 early-stage [American Joint Committee on Cancer (AJCC) stage I or II] and 30 advanced-stage (AJCC stage III or IV) melanomapatients and 48 healthy volunteers were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) utilizing protein chip technology and artificial neural networks. RESULTS: In a first step, a multiprotein classifier was built using a training set of 30 pathologically confirmed melanoma and 24 healthy volunteer serum samples, resulting in good classification accuracy for correct diagnosis and stage classification assignment. Subsequently, our multiprotein classifier was tested in an independent validation set of 30 melanoma and 24 non-cancer serum samples patients, maintained in a good diagnostic accuracy of 98.1% (sensitivity 96.7%, specificity 100%), and 100% stage I/II classification assignment. CONCLUSIONS: Although results remain to be confirmed in larger collective patient cohorts, we could demonstrate the usefulness of proteomic profiling as a sensitive and specific assay to detect melanoma, including non-metastatic melanoma, from the serum.
Authors: Emilia Caputo; Maria Luisa Lombardi; Vincenza Luongo; Ramy Moharram; Pete Tornatore; Giuseppe Pirozzi; John Guardiola; Brian M Martin Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2005-05-05 Impact factor: 3.205
Authors: Alex J Rai; Paul M Stemmer; Zhen Zhang; Bao-Ling Adam; William T Morgan; Rebecca E Caffrey; Vladimir N Podust; Manisha Patel; Lih-Yin Lim; Natalia V Shipulina; Daniel W Chan; O John Semmes; Hon-Chiu Eastwood Leung Journal: Proteomics Date: 2005-08 Impact factor: 3.984
Authors: Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta Journal: Lancet Date: 2002-02-16 Impact factor: 79.321
Authors: Lihua Li; Hong Tang; Zuobao Wu; Jianli Gong; Michael Gruidl; Jun Zou; Melvyn Tockman; Robert A Clark Journal: Artif Intell Med Date: 2004-10 Impact factor: 5.326
Authors: Brian L Hood; Jelena Grahovac; Melanie S Flint; Mai Sun; Nuno Charro; Dorothea Becker; Alan Wells; Thomas P Conrads Journal: J Proteome Res Date: 2010-07-02 Impact factor: 4.466
Authors: Lixia Diao; Charlotte H Clarke; Kevin R Coombes; Stanley R Hamilton; Jack Roth; Li Mao; Bogdan Czerniak; Keith A Baggerly; Jeffrey S Morris; Eric T Fung; Robert C Bast Journal: Cancer Inform Date: 2011-03-14